Sanofi (NASDAQ:SNY) Stock Rating Lowered by Wall Street Zen

Sanofi (NASDAQ:SNY) was downgraded by analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a research note issued to investors on Saturday.

A number of other analysts have also recently weighed in on SNY. UBS Group reaffirmed a “neutral” rating on shares of Sanofi in a report on Friday, January 16th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Sanofi in a research note on Friday, January 16th. Bank of America lowered Sanofi from a “buy” rating to a “neutral” rating in a research report on Thursday, February 12th. Barclays lowered Sanofi from an “overweight” rating to an “equal weight” rating in a report on Tuesday, January 6th. Finally, TD Cowen restated a “hold” rating on shares of Sanofi in a research note on Tuesday, December 30th. Five investment analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Sanofi has an average rating of “Hold” and a consensus price target of $62.67.

Sanofi Stock Performance

Shares of NASDAQ SNY opened at $46.76 on Friday. The company has a quick ratio of 0.73, a current ratio of 1.09 and a debt-to-equity ratio of 0.20. The firm’s 50-day moving average price is $47.55 and its two-hundred day moving average price is $48.58. Sanofi has a 52-week low of $44.62 and a 52-week high of $60.12. The stock has a market capitalization of $114.05 billion, a P/E ratio of 12.99, a P/E/G ratio of 1.21 and a beta of 0.45.

Institutional Trading of Sanofi

A number of large investors have recently added to or reduced their stakes in the business. Flagship Harbor Advisors LLC bought a new position in shares of Sanofi in the fourth quarter valued at $25,000. Financial Consulate Inc. acquired a new stake in shares of Sanofi during the third quarter worth $26,000. Measured Wealth Private Client Group LLC purchased a new stake in shares of Sanofi during the third quarter valued at $29,000. Palisade Asset Management LLC purchased a new stake in shares of Sanofi during the third quarter valued at $30,000. Finally, First Horizon Corp acquired a new position in shares of Sanofi in the 3rd quarter valued at $33,000. 14.03% of the stock is currently owned by institutional investors.

About Sanofi

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.